Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The invention includes a multitude of methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The present invention provides methods for producing sialyloligosaccharides in situ in dairy sources and cheese processing waste streams, prior to, during, or after processing of the dairy source during the cheese manufacturing process. The methods of the present invention use the catalytic activity of &agr;(2-3) trans-sialidases to exploit the high concentrations of lactose and &agr;(2-3) sialosides which naturally occur in dairy sources and cheese processing waste streams to drive the enzymatic synthesis of &agr;(2-3) sialyllactose. &agr;(2-3) sialyloligosaccharides produced according to these methods are additionally encompassed by the present invention. The invention also provides for recovery of the sialyloligosaccharides produced by these methods. The invention further provides a method for producing &agr;(2-3) sialyllactose. The invention additionally provides a method of enriching for &agr;(2-3) sialyllactose in milk using transgenic mammals that express an &agr;(2-3) trans-sialidase transgene.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The present invention provides methods for producing sialyloligosaccharides in situ in dairy sources and cheese processing waste streams, prior to, during, or after processing of the dairy source during the cheese manufacturing process. The methods of the present invention use the catalytic activity of &agr;(2-3) trans-sialidases to exploit the high concentrations of lactose and &agr;(2-3) sialosides which naturally occur in dairy sources and cheese processing waste streams to drive the enzymatic synthesis of &agr;(2-3) sialyllactose. &agr;(2-3) sialyloligosaccharides produced according to these methods are additionally encompassed by the present invention. The invention also provides for recovery of the sialyloligosaccharides produced by these methods. The invention further provides a method for producing &agr;(2-3) sialyllactose. The invention additionally provides a method of enriching for &agr;(2-3) sialyllactose in milk using transgenic mammals that express an &agr;(2-3) trans-sialidase transgene.

Abstract: The present invention provides methods for producing sialyloligosaccharides in situ in dairy sources and cheese processing waste streams, prior to, during, or after processing of the dairy source during the cheese manufacturing process. The methods of the present invention use the catalytic activity of &agr;(2-3) trans-sialidases to exploit the high concentrations of lactose and &agr;(2-3) sialosides which naturally occur in dairy sources and cheese processing waste streams to drive the enzymatic synthesis of &agr;(2-3) sialyllactose. &agr;(2-3) sialyloligosaccharides produced according to these methods are additionally encompassed by the present invention. The invention also provides for recovery of the sialyloligosaccharides produced by these methods. The invention further provides a method for producing &agr;(2-3) sialyllactose. The invention additionally provides a method of enriching for &agr;(2-3) sialyllactose in milk using transgenic mammals that express an &agr;(2-3) trans-sialidase transgene.

Abstract: The present invention is directed to compositions for the treatment of respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenza, Burkholderia (Pseudomonas) cepacia, and a mixture thereof, comprising a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc-, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc-;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.

Abstract: A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I(NeuAc-.alpha.(2-3)-pGal-.beta.(1)-(--X--).sub.m --(--Y--).sub.n -).sub.p -ZwhereinX=a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C;Y=a linking group;Z=a multivalent support;m=0 or 1;n=0 or 1; andp=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula IINeuAc-.alpha.(2-3)-pGal-.beta.(1)-AwhereinA=a group capable of bonding to the p galactose;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C.

Abstract: The present invention is directed to a method of detecting reducing carbohydrates in a complex biological sample. The sample is filtered, subjected to ion exchange chromatography, derivatized, extracted and analyzed by HPLC.

Abstract: A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I(NeuAc-.alpha.(2-3)-pGal-.beta.(1)--(--X--).sub.m --(--Y--).sub.n --).sub.p --ZwhereinX=a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C;Y=a linking group;Z=a multivalent support;m=0 or 1;n=0 or 1; andp=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula IINeuAc-.alpha.(214 3)-pGal-.beta.(1)-AwhereinA=a group capable of bonding to the p galactose;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C.

Abstract: The present invention is directed to a method of treating respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenzae, Burkholderia (Pseudomonas) cepacia and a mixture thereof, by administering a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc--, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc--;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.

Abstract: A method of processing a cheese processing waste stream generated in a cheese-making process, comprising:i) contacting a cheese processing waste stream with an anion exchange resin under conditions to allow negatively charged materials to be absorbed onto said anion exchange resin;ii) removing said anion exchange resin from said cheese processing waste stream and eluting said anion exchange resin with an aqueous solution of a lithium salt to produce an eluent;iii) concentrating said eluent to form a solid comprising a lithium salt and a lithium salt of a cheese processing waste; andiv) washing said solid with an organic solvent, dissolving said lithium salt and leaving said lithium salt of a cheese processing waste as a solid.

Abstract: A method of processing a cheese processing waste stream generated in a cheese-making process is described comprising:i) contacting a cheese processing waste stream with a solvent and extracting a sialyloligosaccharide with said solvent;ii) separating a sialyloligosaccharide containing solvent from said cheese processing waste stream; andiii) isolating a sialyloligosacchride from said sialyloligosaccharide containing solvent.

Abstract: A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I(NeuAc-.alpha.(2-3)-Gal-.beta.(1)-(--X--).sub.m -(--Y--).sub.n -).sub.p -ZwhereinX=a chemical bond or a group capable of linking the galactose to either the linking group Y or the multivalent support Z;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C;Y=a linking group;Z=a multivalent support;m=0 or 1;n=0 or 1; andp=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula IINeuAc-.alpha.(2-3)-Gal-.beta.(1)-AwhereinA=a group capable of bonding to the galactose;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C.

Abstract: A packaging article for the handling of sensitive objects, that includes a semi-rigid foam case in which an elastomeric pad has been molded. A rigid support base is also molded within the case and supported on the elastomeric pad. The support base is covered by a release agent which prevents the casing material from permanently adhering to the support base, thus allowing the support base to shift within the case. A handling stand is secured to the sensitive object and may be used to support the object outside of the case. The handling stand mounts on the support base so that the support base handling stand assembly with the sensitive object mounted thereon floats or shifts within the case on the elastomeric pad without any other object surface contacting the support base.